Overview
Spherix’s coverage of the rheumatoid arthritis segment focuses on tracking brand usage and changes in the treatment paradigm with increasing interest in alternate mechanisms of action in the US and the EU5. We also provide detailed insights in patient characteristics that influence treatment switching decisions.
Services Available
Trending market evolution
Rheumatoid Arthritis (US)
Rheumatoid Arthritis (EU)
Exploring the patient journey
Biologic/Small Molecule Switching in RA (US)
Biologic/Small Molecule Switching in RA (EU)
Benchmarking new brand performance
Artlegia (R-Pharm) in Rheumatoid Arthritis (US)*
*Pending approvals and launch
gauging impact of disruptive events
Multi Specialty Impact of COVID 19 Rheumatology (US)
PCP Treatment of Rheumatology (US)
Pediatric Rheumatology (US)
Rheumatology Biosimilars Today and Tomorrow (US)
The Impact of Biosimilar Usage in Rheumatology (US)